Timothy Olusegun Olanrewaju
@unilorin.edu.ng
Associate Professor, Faculty of Clinical Sciences
University of Ilorin
RESEARCH, TEACHING, or OTHER INTERESTS
Nephrology, Epidemiology, Genetics (clinical), Cardiology and Cardiovascular Medicine
Scopus Publications
Scopus Publications
Anukul Ghimire, Samveg Shah, Utkarsh Chauhan, Kwaifa Salihu Ibrahim, Kailash Jindal, Rumeyza Kazancioglu, Valerie A. Luyckx, Jennifer M. MacRae, Timothy O. Olanrewaju, Robert R. Quinn,et al.
Springer Science and Business Media LLC
Abstract Background There is a lack of contemporary data describing global variations in vascular access for hemodialysis (HD). We used the third iteration of the International Society of Nephrology Global Kidney Health Atlas (ISN-GKHA) to highlight differences in funding and availability of hemodialysis accesses used for initiating HD across world regions. Methods Survey questions were directed at understanding the funding modules for obtaining vascular access and types of accesses used to initiate dialysis. An electronic survey was sent to national and regional key stakeholders affiliated with the ISN between June and September 2022. Countries that participated in the survey were categorized based on World Bank Income Classification (low-, lower-middle, upper-middle, and high-income) and by their regional affiliation with the ISN. Results Data on types of vascular access were available from 160 countries. Respondents from 35 countries (22% of surveyed countries) reported that > 50% of patients started HD with an arteriovenous fistula or graft (AVF or AVG). These rates were higher in Western Europe (n = 14; 64%), North & East Asia (n = 4; 67%), and among high-income countries (n = 24; 38%). The rates of > 50% of patients starting HD with a tunneled dialysis catheter were highest in North America & Caribbean region (n = 7; 58%) and lowest in South Asia and Newly Independent States and Russia (n = 0 in both regions). Respondents from 50% (n = 9) of low-income countries reported that > 75% of patients started HD using a temporary catheter, with the highest rates in Africa (n = 30; 75%) and Latin America (n = 14; 67%). Funding for the creation of vascular access was often through public funding and free at the point of delivery in high-income countries (n = 42; 67% for AVF/AVG, n = 44; 70% for central venous catheters). In low-income countries, private and out of pocket funding was reported as being more common (n = 8; 40% for AVF/AVG, n = 5; 25% for central venous catheters). Conclusions High income countries exhibit variation in the use of AVF/AVG and tunneled catheters. In low-income countries, there is a higher use of temporary dialysis catheters and private funding models for access creation.
Kolawole W Wahab, Bolade Dele-Ojo, Sara Ahmadi-Abhari, Njide Okubadejo, Augustine Odili, Akinyemi Aje, Patrick Idoko, Maruf Gbadamosi, Sani Abubakar, Adeseye Akintunde,et al.
Oxford University Press (OUP)
Abstract There is a need to constantly assess the awareness, treatment, and control of hypertension in Nigeria. This study determined the frequency of undiagnosed hypertension across the six geopolitical zones of Nigeria. We conducted an opportunistic screening of adults aged at least 18 years in the month of May 2021. Participants were recruited by trained volunteers using the May Measurement Month protocol. Blood pressure (BP) was measured using validated digital sphygmomanometers. We defined hypertension as systolic BP ≥ 140 and/or diastolic BP ≥ 90 mmHg and/or the use of BP-lowering medications. A total of 9361 participants (51.5% females) with a mean age of 40.7 ± 15.5 years were screened. Hypertension was present in 3192 (34.1%) of the participants. About half (1491, 46.7%) of the hypertensives were unaware of the diagnosis. Among the 3192 participants with hypertension, less than half (1540, 48.2%) were on antihypertensive medications, while only 36.4% of those on antihypertensive medications had their BP controlled (<140/90 mmHg). About one-third of Nigerians in this opportunistic screening had hypertension, with about half of them being unaware of their diagnosis while only about two out of every five on antihypertensive medications had controlled BP. Urgent health actions are needed in Nigeria to reduce the burden of hypertension and its complications.
Eranga Wijewickrama, Muhammad Rafiqul Alam, Divya Bajpai, Smita Divyaveer, Arpana Iyengar, Vivek Kumar, Ahad Qayyum, Shankar Prasad Yadav, Manjusha Yadla, Silvia Arruebo,et al.
Elsevier BV
Maria Pippias, Gaetano Alfano, Dearbhla M. Kelly, Maria Jose Soler, Letizia De Chiara, Timothy O. Olanrewaju, Silvia Arruebo, Aminu K. Bello, Fergus J. Caskey, Sandrine Damster,et al.
Elsevier BV
Anna Francis, Marina Wainstein, Georgina Irish, Muhammad Iqbal Abdul Hafidz, Titi Chen, Yeoungjee Cho, Htay Htay, Talerngsak Kanjanabuch, Rowena Lalji, Brendon L. Neuen,et al.
Elsevier BV
Elliot Koranteng Tannor, Bianca Davidson, Yannick Nlandu, Peace Bagasha, Workagegnehu Hailu Bilchut, M. Razeen Davids, Hassane M. Diongole, Udeme E. Ekrikpo, Ehab O.A. Hafiz, Kwaifa Salihu Ibrahim,et al.
Elsevier BV
Sabine Karam, Atefeh Amouzegar, Iman Rashed Alshamsi, Saeed M.G. Al Ghamdi, Siddiq Anwar, Mohammad Ghnaimat, Bassam Saeed, Silvia Arruebo, Aminu K. Bello, Fergus J. Caskey,et al.
Elsevier BV
Caner Alparslan, Jolanta Malyszko, Fergus J. Caskey, Mirna Aleckovic-Halilovic, Zdenka Hrušková, Silvia Arruebo, Aminu K. Bello, Sandrine Damster, Jo-Ann Donner, Vivekanand Jha,et al.
Elsevier BV
Viviane Calice-Silva, Javier A. Neyra, Alejandro Ferreiro Fuentes, Krissia Kamile Singer Wallbach Massai, Silvia Arruebo, Aminu K. Bello, Fergus J. Caskey, Sandrine Damster, Jo-Ann Donner, Vivekanand Jha,et al.
Elsevier BV
Winston Wing-Shing Fung, Hyeong Cheon Park, Yosuke Hirakawa, Silvia Arruebo, Aminu K. Bello, Fergus J. Caskey, Sandrine Damster, Jo-Ann Donner, Vivekanand Jha, David W. Johnson,et al.
Elsevier BV
Larisa Prikhodina, Kirill Komissarov, Nikolay Bulanov, Silvia Arruebo, Aminu K. Bello, Fergus J. Caskey, Sandrine Damster, Jo-Ann Donner, Vivekanand Jha, David W. Johnson,et al.
Elsevier BV
Racquel Lowe-Jones, Isabelle Ethier, Lori-Ann Fisher, Michelle M.Y. Wong, Stephanie Thompson, Georges Nakhoul, Shaifali Sandal, Rahul Chanchlani, Sara N. Davison, Anukul Ghimire,et al.
Elsevier BV
Aminu K Bello, Ikechi G Okpechi, Adeera Levin, Feng Ye, Sandrine Damster, Silvia Arruebo, Jo-Ann Donner, Fergus J Caskey, Yeoungjee Cho, M Razeen Davids,et al.
Elsevier BV
Ayo P. Doumatey, Amy R. Bentley, Rufus Akinyemi, Timothy O. Olanrewaju, Adebowale Adeyemo, and Charles Rotimi
Elsevier BV
Timothy O. Olanrewaju, Charlotte Osafo, Yemi R. Raji, Manmak Mamven, Samuel Ajayi, Titilayo O. Ilori, Fatiu A. Arogundade, Ifeoma I. Ulasi, Rasheed Gbadegesin, Rulan S. Parekh,et al.
Elsevier BV
Anjali Gupta, Veeral Saraiya, April Deveaux, Taofik Oyekunle, Klarissa D. Jackson, Omolola Salako, Adetola Daramola, Allison Hall, Olusegun Alatise, Gabriel Ogun,et al.
Springer Science and Business Media LLC
AbstractThere is conflicting evidence on the role of lipid biomarkers in breast cancer (BC), and no study to our knowledge has examined this association among African women. We estimated odds ratios (ORs) and 95% confidence intervals (95% CI) for the association of lipid biomarkers—total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides—with odds of BC overall and by subtype (Luminal A, Luminal B, HER2-enriched and triple-negative or TNBC) for 296 newly diagnosed BC cases and 116 healthy controls in Nigeria. Each unit standard deviation (SD) increase in triglycerides was associated with 39% increased odds of BC in fully adjusted models (aOR: 1.39; 95% CI: 1.03, 1.86). Among post-menopausal women, higher total cholesterol (aOR: 1.65; 95% CI: 1.06, 2.57), LDL cholesterol (aOR: 1.59; 95% CI: 1.04, 2.41), and triglycerides (aOR: 1.91; 95% CI: 1.21, 3.01) were associated with increased odds of BC. Additionally, each unit SD increase in LDL was associated with 64% increased odds of Luminal B BC (aOR 1.64; 95% CI: 1.06, 2.55). Clinically low HDL was associated with 2.7 times increased odds of TNBC (aOR 2.67; 95% CI: 1.10, 6.49). Among post-menopausal women, higher LDL cholesterol and triglycerides were significantly associated with increased odds of Luminal B BC and HER2 BC, respectively. In conclusion, low HDL and high LDL are associated with increased odds of TN and Luminal B BC, respectively, among African women. Future prospective studies can definitively characterize this association and inform clinical approaches targeting HDL as a BC prevention strategy.
Aimé Lumaka, Nadia Carstens, Koenraad Devriendt, Amanda Krause, Benard Kulohoma, Judit Kumuthini, Gerrye Mubungu, John Mukisa, Melissa Nel, Timothy O. Olanrewaju,et al.
Springer Science and Business Media LLC
AbstractThe rich and diverse genomics of African populations is significantly underrepresented in reference and in disease-associated databases. This renders interpreting the Next Generation Sequencing (NGS) data and reaching a diagnostic more difficult in Africa and for the African diaspora. It increases chances for false positives with variants being misclassified as pathogenic due to their novelty or rarity. We can increase African genomic data by (1) making consent for sharing aggregate frequency data an essential component of research toolkit; (2) encouraging investigators with African data to share available data through public resources such as gnomAD, AVGD, ClinVar, DECIPHER and to use MatchMaker Exchange; (3) educating African research participants on the meaning and value of sharing aggregate frequency data; and (4) increasing funding to scale-up the production of African genomic data that will be more representative of the geographical and ethno-linguistic variation on the continent. The RDWG of H3Africa is hereby calling to action because this underrepresentation accentuates the health disparities. Applying the NGS to shorten the diagnostic odyssey or to guide therapeutic options for rare diseases will fully work for Africans only when public repositories include sufficient data from African subjects.
Dominic Mudiayi, Soroush Shojai, Ikechi Okpechi, Emily A. Christie, Kevin Wen, Mostafa Kamaleldin, Mohamed Elsadig Osman, Meaghan Lunney, Bhanu Prasad, Mohamed A. Osman,et al.
Ovid Technologies (Wolters Kluwer Health)
Background. Kidney transplantation (KT) is the optimal treatment for kidney failure and is associated with better quality of life and survival relative to dialysis. However, knowledge of the current capacity of countries to deliver KT is limited. This study reports on findings from the 2018 International Society of Nephrology Global Kidney Health Atlas survey, specifically addressing the availability, accessibility, and quality of KT across countries and regions. Methods. Data were collected from published online sources, and a survey was administered online to key stakeholders. All country-level data were analyzed by International Society of Nephrology region and World Bank income classification. Results. Data were collected via a survey in 182 countries, of which 155 answered questions pertaining to KT. Of these, 74% stated that KT was available, with a median incidence of 14 per million population (range: 0.04–70) and median prevalence of 255 per million population (range: 3–693). Accessibility of KT varied widely; even within high-income countries, it was disproportionately lower for ethnic minorities. Universal health coverage of all KT treatment costs was available in 31%, and 57% had a KT registry. Conclusions. There are substantial variations in KT incidence, prevalence, availability, accessibility, and quality worldwide, with the lowest rates evident in low- and lower-middle income countries. Understanding these disparities will inform efforts to increase awareness and the adoption of practices that will ensure high-quality KT care is provided around the world.
Emmanuel O Sanni, Hannah O Olawumi, Idayat A Durotoye, Timothy O Olanrewaju, Abiola S Babatunde, Olasunkanmi A Shittu, Sikiru A Biliaminu, Khadijat O Omokanye, Mutiat Kehinde Ogunfemi, Olabisi O Akinwumi,et al.
African Journals Online (AJOL)
Background: Functional iron deficiency has been found to be a common cause of poor response to erythropoiesis stimulating agents in anaemic patients with chronic kidney disease (CKD).
 Objectives: Assess the functional iron status of patients with chronic kidney disease.
 Methods: This was a hospital based cross sectional study. The study subjects were chronic kidney disease patients with age and sex matched healthy controls. Full blood count, serum ferritin, soluble transferring receptor, C-reactive protein, serum iron and total iron binding capacity were measured in the patients and healthy controls. Data was analyzed with statistical package for the social sciences software version 22.0. And the level of statistical significance was set at p. value < 0.05.
 Results: The mean ± SD of the age of patient with CKD was 55.0 + 15.4 years, while that of controls was 52.7 + 13.6 years. The mean serum ferritin, serum iron, TIBC and CRP were significantly higher in patients compared with controls (p<0.001, 0.023, <0.001 and 0.001) respectively. Functional iron deficiency was seen in 19.5% of patients with CKD.
 Conclusion: The predominant form of iron deficiency in our study was functional iron deficiency.
 Keywords: Chronic kidney disease; functional iron status; anaemia.
Tomi Akinyemiju, Kelley Jones, Anjali Gupta, Taofik Oyekunle, Veeral Saraiya, April Deveaux, Omolola Salako, Allison Hall, Olusegun Alatise, Gabriel Ogun,et al.
Springer Science and Business Media LLC
Abstract Background The association between obesity and breast cancer (BC) has been extensively studied among US, European and Asian study populations, with often conflicting evidence. However, despite the increasing prevalence of obesity and associated conditions in Africa, the continent with the highest age-standardized BC mortality rate globally, few studies have evaluated this association, and none has examined in relation to molecular subtypes among African women. The current analysis examines the association between body composition, defined by body mass index (BMI), height, and weight, and BC by molecular subtype among African women. Methods We estimated odds ratios (ORs) and 95% confidence intervals (95% CI) for the association between measures of body composition and BC and molecular subtypes among 419 histologically confirmed cases of BC and 286 healthy controls from the Mechanisms for Established and Novel Risk Factors for Breast Cancer in Women of Nigerian Descent (MEND) case-control study. Results Higher BMI (aOR: 0.79; 95% CI: 0.67, 0.95) and weight (aOR: 0.83; 95% CI: 0.69, 0.98) were associated with reduced odds of BC in adjusted models, while height was associated with non-statistically significant increased odds of BC (aOR: 1.07, 95% CI: 0.90, 1.28). In pre/peri-menopausal, but not post-menopausal women, both higher BMI and weight were significantly associated with reduced odds of BC. Further, higher BMI was associated with reduced odds of Luminal A, Luminal B, and HER2-enriched BC among pre/peri-menopausal women, and reduced odds of triple-negative BC among post-menopausal women. Conclusions Higher BMI and weight were associated with reduced odds of BC overall and by molecular subtype among West African women. Larger studies of women of African descent are needed to definitively characterize these associations and inform cancer prevention strategies.
Salisu M. Ishaku, Timothy Olusegun Olanrewaju, Joyce L. Browne, Kerstin Klipstein-Grobusch, Gbenga A. Kayode, Arie Franx, Diederick E. Grobbee, and Charlotte E. Warren
Springer Science and Business Media LLC
Abstract Background Worldwide, hypertensive disorders in pregnancy (HDPs) complicate between 5 and 10% of pregnancies. Sub-Saharan Africa (SSA) is disproportionately affected by a high burden of HDPs and chronic kidney disease (CKD). Despite mounting evidence associating HDPs with the development of CKD, data from SSA are scarce. Methods Women with HDPs (n = 410) and normotensive women (n = 78) were recruited at delivery and prospectively followed-up at 9 weeks, 6 months and 1 year postpartum. Serum creatinine was measured at all time points and the estimated glomerular filtration rates (eGFR) using CKD-Epidemiology equation determined. CKD was defined as decreased eGFR< 60 mL/min/1.73m2 lasting for ≥ 3 months. Prevalence of CKD at 6 months and 1 year after delivery was estimated. Logistic regression analyses were conducted to evaluate risk factors for CKD at 6 months and 1 year postpartum. Results Within 24 h of delivery, 9 weeks, and 6 months postpartum, women with HDPs were more likely to have a decreased eGFR compared to normotensive women (12, 5.7, 4.3% versus 0, 2 and 2.4%, respectively). The prevalence of CKD in HDPs at 6 months and 1 year postpartum was 6.1 and 7.6%, respectively, as opposed to zero prevalence in the normotensive women for the corresponding periods. Proportions of decreased eGFR varied with HDP sub-types and intervening postpartum time since delivery, with pre-eclampsia/eclampsia showing higher prevalence than chronic and gestational hypertension. Only maternal age was independently shown to be a risk factor for decreased eGFR at 6 months postpartum (aOR = 1.18/year; 95%CI 1.04–1.34). Conclusion Prior HDP was associated with risk of future CKD, with prior HDPs being more likely to experience evidence of CKD over periods of postpartum follow-up. Routine screening of women following HDP-complicated pregnancies should be part of a postpartum monitoring program to identify women at higher risk. Future research should report on both the eGFR and total urinary albumin excretion to enable detection of women at risk of future deterioration of renal function.
Rachel Wine, Jovanka Vasilevska-Ristovska, Tonny Banh, Janae Knott, Damien Noone, Rasheed Gbadegesin, Titilayo O. Ilori, Henrietta U. Okafor, Francis Furia, Ifeoma Ulasi,et al.
Elsevier BV
Etty Kruzel-Davila, Barbara Mensah Sankofi, Ernestine Kubi Amos-Abanyie, Anita Ghansah, Alexander Nyarko, Seth Agyemang, Gordon A. Awandare, Moran Szwarcwort-Cohen, Anat Reiner-Benaim, Basem Hijazi,et al.
Frontiers Media SA
Variants in the Apolipoprotein L1 (APOL1) gene (G1-rs60910145, rs73885319, G2-rs71785313) are common in Africans and in individuals of recent African ancestry and are associated with an increased risk of non-diabetic chronic kidney disease (CKD) and in particular of HIV associated nephropathy (HIVAN). In light of the significantly increased risk of HIVAN in carriers of two APOL1 risk alleles, a role in HIV infectivity has been postulated in the mechanism of APOL1 associated kidney disease. Herein, we aim to explore the association between HIV viremia and APOL1 genotype. In addition, we investigated interaction between BK and JC viruria, CKD and HIV viremia. A total of 199 persons living with HIV/AIDS (comprising 82 CKD cases and 117 controls) from among the participants in the ongoing Human Heredity and Health in Africa (H3Africa) Kidney Disease Research Network case control study have been recruited. The two APOL1 renal risk alleles (RRA) genotypes were associated with a higher risk of CKD (OR 12.6, 95% CI 3.89–40.8, p &lt; 0.0001). Even a single APOL1 RRA was associated with CKD risk (OR 4.42, 95% CI 1.49–13.15, p = 0.007). The 2 APOL1 RRA genotypes were associated with an increased probability of having HIV viremia (OR 2.37 95% CI 1.0–5.63, p = 0.05). HIV viremia was associated with increased CKD risk (OR 7.45, 95% CI 1.66–33.35, P = 0.009) and with a significant reduction of JC virus urine shedding (OR 0.35, 95% CI 0.12–0.98, p = 0.046). In contrast to prior studies, JC viruria was not associated with CKD but was restricted in patients with HIV viremia, regardless of CKD status. These findings suggest a role of APOL1 variants in HIV infectivity and emphasize that JC viruria can serve as biomarker for innate immune system activation.
Fidelis Oguejiofor, Daniel S. Kiggundu, Aminu K. Bello, Charles R. Swanepoel, Gloria Ashuntantang, Vivekanand Jha, David C.H. Harris, Adeera Levin, Marcello Tonelli, Abdou Niang,et al.
Elsevier BV
Davies Adeloye, Eyitayo O. Owolabi, Dike B. Ojji, Asa Auta, Mary T. Dewan, Timothy O. Olanrewaju, Okechukwu S. Ogah, Chiamaka Omoyele, Nnenna Ezeigwe, Rex G. Mpazanje,et al.
Wiley
Improved understanding of the current burden of hypertension, including awareness, treatment, and control, is needed to guide relevant preventative measures in Nigeria. A systematic search of studies on the epidemiology of hypertension in Nigeria, published on or after January 1990, was conducted. The authors employed random‐effects meta‐analysis on extracted crude hypertension prevalence, and awareness, treatment, and control rates. Using a meta‐regression model, overall hypertension cases in Nigeria in 1995 and 2020 were estimated. Fifty‐three studies (n = 78 949) met our selection criteria. Estimated crude prevalence of pre‐hypertension (120‐139/80‐89 mmHg) in Nigeria was 30.9% (95% confidence interval [CI]: 22.0%‐39.7%), and the crude prevalence of hypertension (≥140/90 mmHg) was 30.6% (95% CI: 27.3%‐34.0%). When adjusted for age, study period, and sample, absolute cases of hypertension increased by 540% among individuals aged ≥20 years from approximately 4.3 million individuals in 1995 (age‐adjusted prevalence 8.6%, 95% CI: 6.5‐10.7) to 27.5 million individuals with hypertension in 2020 (age‐adjusted prevalence 32.5%, 95% CI: 29.8‐35.3). The age‐adjusted prevalence was only significantly higher among men in 1995, with the gap between both sexes considerably narrowed in 2020. Only 29.0% of cases (95% CI: 19.7‐38.3) were aware of their hypertension, 12.0% (95% CI: 2.7‐21.2) were on treatment, and 2.8% (95% CI: 0.1‐5.7) had at‐goal blood pressure in 2020. Our study suggests that hypertension prevalence has substantially increased in Nigeria over the last two decades. Although more persons are aware of their hypertension status, clinical treatment and control rates, however, remain low. These estimates are relevant for clinical care, population, and policy response in Nigeria and across Africa.